UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event ~~reported~~Reported): ~~April~~May 1914, 2026

MODULAR MEDICAL, INC.

(Exact Name of Registrant as Specified in Charter)

001-41277

(Commission File Number)

Nevada		87-0620495
(State or Other Jurisdiction of Incorporation)		(I.R.S. Employer Identification Number)

10740 Thornmint Road

San Diego, California 92127

(Address of principal executive offices, with zip code)

(858) 800-3500

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		MODD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 15.0102 ~~Entry~~Departure ~~into~~of aDirectors ~~Material~~or ~~Definitive~~Certain ~~Agreement~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 19, 2026, Modular Medical, Inc. (the “Company”) entered into a Placement Agency Agreement (the “Agreement”) with Maxim Group LLC (the “Placement Agent”), relating to a registered direct offering (the “Offering”) of 750,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock~~”),~~ ~~referred~~Option toAwards ~~as the “Shares.” The gross proceeds~~ to ~~the~~Named ~~Company~~Executive from the Offering will be approximately $3.375 million, before deducting the Placement Agent fee and other offering expenses. The Offering is expected to close on April 21, 2026 (the “Closing Date”).Officers

~~Pursuant~~On May 14, 2026, the board of directors of Modular Medical, Inc. (the “Company”) awarded 11,218 stock options to Paul DiPerna, the ~~Agreement~~Company’s Chairman, President, Chief Financial Officer and Treasurer, and 4,674 stock options to Kevin Schmid, the Company’s ~~agreed~~Chief toOperating ~~pay~~Officer. The stock options have an exercise price of $3.46 per share of common stock and vest as follows: one-third of the ~~Placement~~shares ~~Agent~~subject ato ~~cash~~the ~~fee~~option ~~equal~~on May 14, 2027 and as to 7%1/24th of the ~~gross~~remaining ~~proceeds~~shares ~~received~~subject ~~from~~to the ~~Offering~~option ~~and~~on a monthly basis thereafter, subject to ~~reimburse~~continued service on each ~~the~~vesting ~~Placement~~date. ~~Agent~~The ~~for~~stock ~~its~~options ~~expenses~~expire ~~incurred~~on inMay ~~connection~~14, ~~with~~2036. ~~the~~The ~~Offering~~stock inoptions anwere ~~amount~~awarded uppursuant to ~~$75~~the Company’s Amended and Restated 2017 Equity Incentive Plan,~~000~~ as amended.

The ~~Offering~~foregoing ~~was~~description ~~made pursuant~~of tothe anstock ~~effective~~option awards ~~registration~~does ~~statement~~not onpurport ~~Form~~to ~~S-3~~be ~~(Registration~~complete ~~Statement~~and ~~No.~~is ~~333-~~qualified ~~287313)~~in ~~previously~~its ~~filed~~entirety ~~with~~by ~~the~~reference ~~Securities and~~to ~~Exchange Commission (~~the ~~“SEC”)~~full ontext ~~May~~of ~~15,~~the ~~2025~~form ~~and~~of ~~declared~~Notice ~~effective~~of byGrant ~~the~~of Stock ~~SEC~~Option onAward ~~May~~and 22Agreement, ~~2025,~~which ~~and~~is aattached ~~final~~hereto ~~prospectus supplement~~as ~~relating~~Exhibit to10.1, ~~the~~and ~~Offering~~is ~~dated~~incorporated ~~April~~herein ~~19,~~by ~~2026~~reference.

~~Pursuant~~Item to the Agreement, each of the Company’s directors and executive officers entered into “lock-up” agreements that, subject to certain exceptions, prohibit, without the prior written consent of the Placement Agent, the sale, transfer, or other disposition of securities of the Company for a period of 90 days from the date of the Agreement9.01 ~~Pursuant~~Financial toStatements ~~the Agreement, the Company has agreed not to, subject to certain conditions~~ and exceptions, offer, pledge, sell, contract to sell, or sell any option, right or warrant to purchase, lend or otherwise transfer or dispose, directly or indirectly, any shares of capital stock or any securities convertible into or exercisable or exchangeable for shares of capital stock, affect or enter into an agreement to effect any issuance by the Company or its subsidiaries of Common Stock or Common Stock equivalents (or a combination of units thereof) for a period of 45 days from the Closing DateExhibits.

~~The~~(d) ~~foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed herewith as Exhibit 1~~Exhibits.~~1 to this Current Report on Form 8-K and is incorporated herein by reference.~~

A copy of the legal opinion of Lucosky Brookman, LLP relating to the Shares is attached hereto as Exhibit 5.1.

10.1		Form of Notice of Grant of Stock Option Award and Agreement pursuant to the Modular, Medical Inc. Amended and Restated 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.16 to the Company’s Form 10-Q filed on February 13, 2020).
104		The cover page of this Current Report on Form 8-K formatted in Inline XBRL 1.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.1

~~Item 8.01 Other Events.~~SIGNATURE

~~The~~Pursuant ~~Company~~to ~~issued a press release announcing~~ the ~~pricing~~requirements of the ~~Offering~~Securities Exchange onAct ~~April~~of 191934, ~~2026.~~the Aregistrant ~~copy~~has ofduly caused this ~~press~~report ~~release~~to isbe ~~attached~~signed ~~hereto~~on asits ~~Exhibit~~behalf ~~99.1 and~~by isthe ~~incorporated~~undersigned ~~herein~~hereunto byduly ~~reference~~authorized.

	MODULAR MEDICAL, INC.

Date: May 20, 2026	By:	/s/ James Besser
		James Besser
		Chief Executive Officer

~~Item 9.01 Financial Statements and Exhibits~~2

(d) Exhibits

The following exhibits are filed with this report:

Exhibit Number		Exhibit Description
1.1		Placement Agency Agreement, dated as of April 19, 2026, between the Company and Maxim Group LLC
5.1		Opinion of Lucosky Brookman, LLP
23.1		Consent of Lucosky Brookman, LLP (included in Exhibit 5.1)
99.1		Press Release dated April 19, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MODULAR MEDICAL, INC.
Date: April 21, 2026	By:	/s/ James E. Besser
		James E. Besser
		Chief Executive Officer

Filing Compare · Modular Medical, Inc.